Finally, we implanted wildtyper or MET-deficient GL-261 tumors in immunocompetent mice and analyzed the immune cells in the tumor microenvironment when treated with or without tepotinib or irradiation or both at an early timepoint by flow cytometry using the gating strategy shown in Fig. 8B. At an early stage, no major differences in immune cell populations were found in response to either treatment in GL-261 wildtype tumors. Here, MET is linked to neoplasm.